Skip to main content
. 2023 Dec 12;29(12):3050–3058. doi: 10.1038/s41591-023-02600-4

Fig. 3. Comparison of age-standardized cervical cancer incidence reduction as a measure of the benefits-to-harms profile of each strategy.

Fig. 3

a, Lifetime number of pre-cancer treatments. b, Lifetime number of additional pre-term deliveries due to pre-cancer treatment. ASCUS, atypical squamous cells of undetermined significance; yrly, yearly; yrs, years. +There could be multiple treatments in the same woman over her lifetime. *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV 16/18 positive women treated after assessment of eligibility for ablative treatment. Women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.